结核病短程治疗研究:回顾与展望

doi:10.19982/j.issn.1000-6621.20240219

中国防痨杂志 ›› 2024, Vol. 46 ›› Issue (9): 991-997.doi: 10.19982/j.issn.1000-6621.20240219

结核病短程治疗研究:回顾与展望

李杨¹^,², 孙峰¹^,², 张文宏¹^,²()

¹国家传染病医学中心/复旦大学附属华山医院,上海 200040
²上海市传染病与生物安全应急响应重点实验室/上海市感染与免疫科技创新中心,上海 200040

收稿日期:2024-05-30 出版日期:2024-09-10 发布日期:2024-08-30
通信作者: 张文宏,Email:wenhongzhang@fudan.edu.cn
基金资助:
上海申康医院发展中心临床三年行动计划资助(SHDC2020CR1011B);上海市加强公共卫生体系建设三年行动计划(2020—2022年)(GWV-3.1);国家自然科学基金青年基金(82102406);上海申康医院发展中心模拟RCT项目(SHDC2024CRI047);上海市科技重大专项(HS2021SHZX001)

Short-course treatment for tuberculosis: past achievements and future directions

Li Yang¹^,², Sun Feng¹^,², Zhang Wenhong¹^,²()

¹National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China
²Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Sci-Tech Inno Center for Infection and Immunity, Shanghai 200040, China

Received:2024-05-30 Online:2024-09-10 Published:2024-08-30
Contact: Zhang Wenhong, Email: wenhongzhang@fudan.edu.cn
Supported by:
Clinical Research Plan of SHDC(SHDC2020CR1011B);The Three-year (2020—2022) Action Plan Project for Public Health from Shanghai Municipal Health Commission(GWV-3.1);National Natural Science Foundation of China(82102406);RCT Duplicate program of SHDC(SHDC2024CRI047);Shanghai Municipal Science and Technology Major Project(HS2021SHZX001)

摘要/Abstract

摘要：

目前,结核病疫情下降速度缓慢,距离世界卫生组织“终止结核病策略”所设定的里程碑目标仍有较大差距,研发并应用有效的短程治疗方案变得至关重要。本文旨在回顾过去几十年中结核病短程治疗的发展历程,评估当前治疗方法的有效性,以期为未来结核病短程治疗策略的优化提供依据和参考。通过系统性回顾文献和最新的临床试验数据,笔者分析了多种短程治疗方案的疗效、安全性,以及应用场景;并分析、归纳目前短程治疗的主要策略。尽管存在挑战,但通过新型药物的开发、药物剂量优化和更精准的患者评估,结核病的短程治疗有望在未来几年内取得显著进展。

关键词: 结核, 临床方案, 治疗应用, 总结性报告(主题)

Abstract:

The global decline in tuberculosis (TB) incidence has been disappointingly slow, significantly lagging behind the milestones set by the World Health Organization’s End TB Strategy. Consequently, the development and implementation of effective short-course treatment regimens have become imperative. This review aims to examine the progress of short-course TB treatments over the past few decades and evaluate the efficacy of current therapeutic approaches, providing essential references and support for optimizing future treatment strategies. Through a systematic review of the literature and the latest clinical trial data, we analyzed the efficacy, safety, and application scenarios of various short-course treatment regimens. Furthermore, we summarized the main strategies for current short-course treatments. Despite existing challenges, significant progress in tuberculosis short-course treatment is anticipated in the coming years, driven by the development of novel drugs, dose optimization, and more precise patient evaluation.

Key words: Tuberculosis, Clinical protocols, Therapeutic uses, Consensus reports

中图分类号:

R52
R825.2

李杨, 孙峰, 张文宏. 结核病短程治疗研究:回顾与展望[J]. 中国防痨杂志, 2024, 46(9): 991-997. doi: 10.19982/j.issn.1000-6621.20240219

Li Yang, Sun Feng, Zhang Wenhong. Short-course treatment for tuberculosis: past achievements and future directions[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 991-997. doi: 10.19982/j.issn.1000-6621.20240219

参考文献 50

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1):15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	Millington KA, White RG, Lipman M, et al. The 2023 UN high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis. Lancet Respir Med, 2024, 12(1): 10-13. doi:10.1016/S2213-2600(23)00409-5.
[3]	李杨, 吴利俊, 王钰琛, 等. 2016—2021年全球结核研究现状及热点:基于VOSviewer的可视化分析. 复旦学报(医学版), 2022, 49(2): 159-167. 10.3969/j.issn.1672-8467.2022.02.001.
[4]	Lee A, Xie YL, Barry CE, et al. Current and future treatments for tuberculosis. BMJ, 2020, 368: m216. doi:10.1136/bmj.m216.
[5]	Bignall J, Rist N. An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis. A trial directed by the Committee on Treatment and the Committee on Bacteriology and Immunology of the International Union against Tuberculosis. Bull Int Union Tuberc, 1964, 34: 79-191.
[6]	McCune RM Jr, McDermott W, Tompsett R.The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. Ⅱ. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med, 1956, 104(5): 763-802. doi:10.1084/jem.104.5.763.
[7]	Grumbach F. Activity of rifampicin on experimental tuberculosis in mice. The development of resistance to rifampicin. Therapeutic effects of combinations of different drugs with rifampicin. Antibiot Chemother, 1970, 16: 392-405.
[8]	Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet, 1972, 1(7760): 1079-1085.
[9]	Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet, 1974, 2(7875): 237-240.
[10]	Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet, 1975, 1(7899): 119-124.
[11]	Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study. Am Rev Respir Dis, 1978, 118(1): 39-48. doi:10.1164/arrd.1978.118.1.39.
[12]	Aguilar Diaz JM, Abulfathi AA, Te Brake LH, et al. New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians. Respiration, 2023, 102(2): 83-100. doi:10.1159/000528274.
[13]	常蕴青, 顾瑾, 付亮, 等. 耐多药结核病短程治疗研究进展. 中华传染病杂志, 2018, 36(11): 697-700. doi:10.3760/cma.j.issn.1000-6680.2018.11.015.
[14]	Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med, 2021, 384(18): 1705-1718. doi:10.1056/NEJMoa2033400.
[15]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment. Geneva: World Health Organization, 2022.
[16]	Feng Z, Miao Y, Peng Y, et al. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T)(ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial. BMC Infect Dis, 2023, 23(1): 300. doi:10.1186/s12879-023-08264-2.
[17]	Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. N Engl J Med, 2023, 388(10): 873-887. doi:10.1056/NEJMoa2212537.
[18]	Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med, 2019, 380(13): 1201-1213. doi:10.1056/NEJMoa1811867.
[19]	Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet, 2022, 400(10366): 1858-1868. doi:10.1016/S0140-6736(22)02078-5.
[20]	Hewison C, Khan U, Bastard M, et al. Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort. Clin Infect Dis, 2022, 75(6): 1006-1013. doi:10.1093/cid/ciac019.
[21]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med, 2020, 382(10): 893-902. doi:10.1056/NEJMoa1901814.
[22]	Nyang’wa BT, Berry C, Kazounis E, et al. A 24-week, alloral regimen for rifampin-resistant tuberculosis. N Engl J Med, 2022, 387(25): 2331-2343. doi:10.1056/NEJMoa-2117166.
[23]	Nyang’wa BT, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med, 2024, 12(2): 117-128. doi:10.1016/S2213-2600(23)00389-2.
[24]	World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2022.
[25]	Weng T, Sun F, Li Y, et al. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infect Dis, 2021, 21(1): 183. doi:10.1186/s12879-021-05870-w.
[26]	Mok J, Lee M, Kim DK, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet, 2022, 400(10362): 1522-1530. doi:10.1016/S0140-6736(22)01883-9.
[27]	Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study). Am J Respir Crit Care Med, 2022, 205(10): 1214-1227. doi:10.1164/rccm.202107-1779OC.
[28]	Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis, 2023, 76(3): e938-e946. doi:10.1093/cid/ciac528.
[29]	Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011, 365(23): 2155-2166. doi:10.1056/NEJMoa1104875.
[30]	Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med, 2018, 379(5): 440-453. doi:10.1056/NEJMoa1714283.
[31]	Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi:10.1056/NEJMoa1806808.
[32]	Ruan QL, Huang XT, Yang QL, et al. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial. Clin Microbiol Infect, 2021, 27(4): 576-582. doi:10.1016/j.cmi.2020.06.008.
[33]	Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018, 52(6):1801470. doi:10.1183/13993003.01470-2018.
[34]	Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis, 2022, 22(4): 496-506. doi:10.1016/S1473-3099(21)00470-9.
[35]	Azimi T, Khoshnood S, Asadi A, et al. Linezolid resistance in multidrug-resistant Mycobacterium tuberculosis: A systematic review and meta-analysis. Front Pharmacol, 2022,13: 955050. doi:10.3389/fphar.2022.955050.
[36]	Diacon AH. Two Steps Forward, One Step Back. N Engl J Med, 2022, 387(25): 2380-2381. doi:10.1056/NEJMe2214707.
[37]	Ramey ME, Kaya F, Bauman AA, et al. Drug distribution and efficacy of the DprE 1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model. Antimicrob Agents Chemother, 2023, 67(11): e0059723. doi:10.1128/aac.00597-23.
[38]	Holt E. Phase 2 trial of a novel tuberculosis drug launched. Lancet Microbe, 2024, 5(4): e316. doi:10.1016/S2666-5247(23)00401-9.
[39]	Boeree MJ, Lange C, Thwaites G, et al. UNITE4TB: a new consortium for clinical drug and regimen development for TB. Int J Tuberc Lung Dis, 2021, 25(11): 886-889. doi:10.5588/ijtld.21.0515.
[40]	Fox GJ, Nguyen CB, Nguyen TA, et al. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ Open, 2020, 10(1):e033945. doi:10.1136/bmjopen-2019-033945.
[41]	Peloquin CA. Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci, 2001, 953: 157-164. doi:10.1111/j.1749-6632.2001.tb11374.x.
[42]	Velásquez GE, Brooks MB, Coit JM, et al. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial. Am J Respir Crit Care Med, 2018, 198(5): 657-666. doi:10.1164/rccm.201712-2524OC.
[43]	Onorato L, Gentile V, Russo A, et al. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect, 2021, 27(6): 830-837. doi:10.1016/j.cmi.2021.03.031.
[44]	Jindani A, Atwine D, Grint D, et al. Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis. NEJM Evid, 2023, 2(9): EVIDoa2300054. doi:10.1056/EVIDoa-2300054.
[45]	宋凌云, 张忆琳, 孙峰, 等. 持续提高耐药结核病治疗安全性的挑战与对策. 中华传染病杂志, 2023, 41(12): 797-801. doi:10.3760/cma.j.cn311365-20230729-00020.
[46]	胡艳梅, 罗丹霖, 李杨, 等. 利奈唑胺治疗耐多药肺结核患者的不良反应分析. 中华传染病杂志, 2022, 40(8): 476-482. doi:10.3760/cma.j.cn311365-20210710-00247.
[47]	Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med, 2022, 387(9): 810-823. doi:10.1056/NEJMoa2119430.
[48]	Fregonese F, Apriani L, Barss L, et al. High dose rifampin for 2 months vs standard dose rifampin for 4 months, to treat TB infection: Protocol of a 3-arm randomized trial (2R2). PLoS One, 2023, 18(2): e0278087. doi:10.1371/journal.pone.0278087.
[49]	Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med, 2022, 386(10): 911-922. doi:10.1056/NEJMoa2104535.
[50]	初乃惠, 周文强. 耐药结核病的诊治进展. 中华传染病杂志, 2021, 39(7): 385-391. doi:10.3760/cma.j.cn311365-20210414-00133.

结核病短程治疗研究:回顾与展望

Short-course treatment for tuberculosis: past achievements and future directions

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 50

相关文章 15

编辑推荐

Metrics

本文评价

[1]	康媛媛, 安立文, 李春妍, 徐诗晴. 基于中医辨证体系的男性泌尿系统结核诊断思路与特色疗法探析[J]. 中国防痨杂志, 2025, 47(S2): 1-3.
[2]	廖影, 高春洁, 庞艳, 赵静, 陈静, 何高琴, 涂龙成, 游茂林, 王蕾. 重庆市梁平区肺结核传播动力学模型的构建与应用[J]. 中国防痨杂志, 2025, 47(S2): 17-22.
[3]	陈丽, 秦雪玲, 张念伦, 于桂芹. 2020—2023年65岁及以上老年人肺结核患者耐药情况及影响因素分析[J]. 中国防痨杂志, 2025, 47(S2): 23-26.
[4]	熊丽芬, 李思, 杨茜茹, 杨坤彦, 王宇. 2016—2024年云南省西双版纳州病原学阳性肺结核患者特征及治疗2个月末痰菌未阴转的影响因素分析[J]. 中国防痨杂志, 2025, 47(S2): 27-31.
[5]	曾霞波, 李丹, 李汝霞, 黄学勇, 尹进, 张挣瑜, 苏倩. 重庆市老年2型糖尿病患者结核病核心知识知晓率调查研究[J]. 中国防痨杂志, 2025, 47(S2): 32-36.
[6]	毛志伟, 章秀芝, 程鑫, 徐丽芳. 江西省上饶市2023—2024年肺结核及流感发病率与空气PM2.5的相关性分析[J]. 中国防痨杂志, 2025, 47(S2): 37-39.
[7]	杜润泽, 蔡晓宇, 徐韬, 牙克甫·阿卜力孜, 王婷, 盛伟斌, 买尔旦·买买提. 结合XGBoost与logistic回归的脊柱感染性疾病鉴别诊断模型[J]. 中国防痨杂志, 2025, 47(S2): 40-47.
[8]	付敏, 周越, 陈方, 程静. 肺结核并发支气管扩张患者发生院内感染的风险预测模型研究[J]. 中国防痨杂志, 2025, 47(S2): 48-50.
[9]	杜润泽, 蔡晓宇, 徐韬, 牙克甫·阿卜力孜, 高书涛, 王婷, 盛伟斌, 买尔旦·买买提. 基于九种机器学习算法的脊柱结核与布鲁氏菌性脊柱炎鉴别诊断模型研究[J]. 中国防痨杂志, 2025, 47(S2): 55-59.
[10]	张鑫, 邢惟俊, 杨志伟, 姚文, 徐芳, 杨增伟, 李东辉, 同重湘. 血清γ-干扰素和白细胞介素2水平对老年肺结核的诊断价值[J]. 中国防痨杂志, 2025, 47(S2): 63-65.
[11]	刘家秀, 李同心, 蒋玲, 高静. 降钙素原和白介素-6联合检测用于辅助诊断肺结核的价值分析[J]. 中国防痨杂志, 2025, 47(S2): 66-69.
[12]	陈磊, 贺晓英, 乔治成, 单晓雪, 潘兆宝, 李鹏, 袁素云. IFN-γ和IL-2在诊断活动性肺结核中的应用价值[J]. 中国防痨杂志, 2025, 47(S2): 70-73.
[13]	王路. 多层螺旋CT在肺结核诊断中的准确性与临床价值研究[J]. 中国防痨杂志, 2025, 47(S2): 74-77.
[14]	俞亮, 顾龙飞, 黄佳伟. 结核性脑膜炎的影像学特征与诊断准确性分析[J]. 中国防痨杂志, 2025, 47(S2): 84-86.
[15]	王伟, 孟敏. 血糖控制对糖尿病合并肺结核影像学表现的影响分析[J]. 中国防痨杂志, 2025, 47(S2): 87-89.